Arca
Skip to content
Tools
Tools

Fibrosis

Drug research and approvals for fibrosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 754 studies of fibrosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 141 drug trials for it since 2013, FDA has 33 approved and 179 open orphan designations naming it, and the EU has 21 authorised medicines for it.

  • Recruiting worldwide: 754
  • Trials authorized in Canada: 141
  • FDA orphan approvals: 33
  • EU medicines: 21

Recruiting Now

Newest start dates first, of 754 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

5 approved, 1 in phase 3, 5 in phase 2, 10 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Ribavirin, Phytonadione, Furosemide, Spironolactone, Ethacrynic acid

Peginterferon ALFA-2B
Phase 3 Interferon alpha/beta receptor agonist
Pentoxifylline
Phase 2 Adenosine A2 receptor antagonist
Vitamin e
Phase 2
Pravastatin
Phase 2 HMG-CoA reductase inhibitor
Lenumlostat
Phase 2 Lysyl oxidase homolog 2 inhibitor
Diphenhydramine
Phase 1 Histamine H1 receptor antagonist
Famotidine
Phase 1 Histamine H2 receptor antagonist
Ursodiol
Phase 1 Bile acid receptor FXR agonist
Interferon
Phase 1
Bifendate
Phase 1
Pirfenidone
Phase 1 Unknown
Olitigaltin
Phase 1 Galectin-3 inhibitor
Ziritaxestat
Phase 1 Autotaxin inhibitor
Fapi GA-68
Early phase 1

How Its Trials Ended

3,487 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 781 whose ending is known, 41% met their primary endpoint, 10% missed it and 49% stopped early.

  • Completed, result not reported1,43641%
  • Ongoing72521%
  • Status unknown54516%
  • Met its primary endpoint3229%
  • Stopped: other or unclear2046%
  • Stopped: enrollment or feasibility862%
  • Missed its primary endpoint802%
  • Stopped: lack of efficacy371%
  • Stopped: sponsor or business decision321%
  • Stopped: funding120%
  • Stopped: safety80%

Trials Authorized in Canada

The 10 newest of 141; search them all in Canada trials
Nov 10, 2026A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose range finding study to evaluate the efficacy, safety, and…CSL787CSLPending
Oct 23, 2026A randomised, double-blind, placebo-controlled phase IIa trial to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety, and tolerability of bi…BI 3810477Boehringer Ingelheim (Canada) Ltd LteePending
Aug 21, 2026A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of nalbuphine extended-release tablets for the treatment of chronic…NalbuphineTrevi Therapeutics IncPending
Jul 3, 2026A phase 2, multicenter, randomized, active-controlled study to assess the safety and efficacy of ang003 at two different dose levels in subjects with exocrine…ANG003 (lipase V325, protease, amylase) / creonAnagram Therapeutics, Inc.Pending
Jun 26, 2026A randomized, double-blind, head-to-head phase 3 trial to evaluate the efficacy and safety of lyt-100 (deupirfenidone) compared to pirfenidone at 52 weeks in…Deupirfenidone (LYT-100) / pirfenidonePuretech Lyt 100, IncOngoing
May 29, 2026Nerandomilast added to mycophenolate for treatment of pulmonary fibrosis (neram-pf): a single-arm prospective studyNerandomilast (bi 1015550)Ubc Centre For Heart Lung Innovation, St. Paul'S HospitalOngoing
Apr 17, 2026A randomized, double-blind, placebo-controlled, phase 2 clinical trial of the efficacy and safety of mnkd-201 (nintedanib dry powder inhalation) in patients…Nintedanib (MNKD-201)MannKindOngoing
Apr 10, 2026A phase IIb study to evaluate the efficacy, safety, and tolerability of azd8965 in participants with idiopathic pulmonary fibrosis (ipf) (arginaut)AZD8965AstraZeneca PharmaceuticalsOngoing
Apr 7, 2026An open-label, multi-center, long-term extension study to evaluate the long-term safety and tolerability of admilparant in participants with pulmonary fibrosisAdmilparant (BMS-986278)Bristol-Myers SquibbPending
Mar 20, 2026A randomized, double-blinded, placebo-controlled, parallel-group, phase 2a participants with non-cystic fibrosis bronchiectasis (ncfb) study to assess the…SAR445399Sanofi-Aventis Canada IncOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 212
Mar 27, 2026AlyftrekTreatment of cystic fibrosis (CF) in adult and pediatric patients 6 years of age and older who have a clinical diagnosis of CF and who have…Vertex Pharmaceuticals IncorporatedApproved
Mar 27, 2026TrikaftaTreatment of cystic fibrosis (CF) in adult and pediatric patients aged 2 years and older who have a clinical diagnosis of CF and who have…Vertex Pharmaceuticals IncorporatedApproved
Oct 7, 2025JascaydTreatment of idiopathic pulmonary fibrosis (IPF) in adult patientsBoehringer Ingelheim Pharmaceuticals, Inc.Approved
Dec 20, 2024AlyftrekTreatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del mutation or another responsive…Vertex Pharmaceuticals IncorporatedApproved
Dec 20, 2024TrikaftaTreatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis…Vertex Pharmaceuticals IncorporatedApproved
May 3, 2023KalydecoTreatment of cystic fibrosis (CF) in patients age 1 month and older who have at least one mutation in the CFTR gene that is responsive to…Vertex Pharmaceuticals, Inc.Approved
Apr 26, 2023TrikaftaTreatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis…Vertex Pharmaceuticals IncorporatedApproved
Sep 2, 2022OrkambiTreatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR geneVertex Pharmaceuticals Inc.Approved
Jun 8, 2021TrikaftaTreatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis…Vertex Pharmaceuticals IncorporatedApproved
Dec 21, 2020TrikaftaTreatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis…Vertex Pharmaceuticals IncorporatedApproved
Dec 21, 2020SymdekoTreatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation or who have at least one…Vertex Pharmaceuticals Inc.Approved
Dec 21, 2020KalydecoTreatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the cystic fibrosis transmembrane conductance…Vertex Pharmaceuticals, Inc.Approved
Oct 30, 2020Bronchitol®As add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use…Pharmaxis Europe LimitedApproved
Sep 24, 2020KalydecoKALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene…Vertex Pharmaceuticals, Inc.Approved
Oct 21, 2019TrikaftaTRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation…Vertex Pharmaceuticals IncorporatedApproved

Medicines Authorised in the EU

Newest first; 15 of 21
Jul 15, 2026JascaydNerandomilastBoehringer Ingelheim International GmbHEMA ↗
Mar 26, 2026KayshildSemaglutideNovo Nordisk A/SEMA ↗
Nov 18, 2025BrinsupriBrensocatibInsmed Netherlands B.V.EMA ↗
Aug 22, 2025Nintedanib ViatrisNintedanib · genericViatris LimitedEMA ↗
Aug 18, 2025RezdiffraResmetiromMadrigal Pharmaceuticals EU LimitedEMA ↗
Jun 30, 2025AlyftrekDeutivacaftor / tezacaftor / vanzacaftor · orphanVertex Pharmaceuticals (Ireland) LimitedEMA ↗
Apr 19, 2024Nintedanib AccordNintedanib · genericAccord Healthcare S.L.U.EMA ↗
Jan 10, 2023Pirfenidone ViatrisPirfenidone · genericViatris LimitedEMA ↗
Jun 20, 2022Pirfenidone axunio (previously Pirfenidone AET)Pirfenidone · genericAxunio Pharma GmbHEMA ↗
Aug 21, 2020KaftrioIvacaftor;tezacaftor;elexacaftor · orphanVertex Pharmaceuticals (Ireland) LimitedEMA ↗
Feb 18, 2019Vantobra (previously Tobramycin PARI)TobramycinPari Pharma GmbHEMA ↗
Oct 31, 2018SymkeviTezacaftor;ivacaftor · orphanVertex Pharmaceuticals (Ireland) LimitedEMA ↗
Nov 19, 2015OrkambiLumacaftor;ivacaftorVertex Pharmaceuticals (Ireland) LimitedEMA ↗
Mar 25, 2015QuinsairLevofloxacinChiesi Farmaceutici S.p.AEMA ↗
Jan 14, 2015OfevNintedanibBoehringer Ingelheim International GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.